With Continuous Failure Active Biotech Regains Global Rights for Laquinimod from Teva

Shots:

• Teva was assessing laquinimod since 2007, globally the drug completed three P-III studies ALLEGRO, BRAVO and CONCERTO in rrMS, P-II study ARPEGGIO in primary progressive MS and single P-II LEGATO-HD trial in Huntington’s Disease(HD)
• The P-II LEGATO-HD trial in HD fails to meet 1EP@12 mos, additionally in Dec 2017, P-II POC study of laquinimod didn’t meet 1EP and 2EP in Primary Progressive MS
• Laquinimod a qd PO selective aryl hydrocarbon receptor (AhR), for treatment of MS and HD and is also being studied for Crohn’s disease and Lupus

Click here to read full press release/ article | Ref: Active Biotech | Image: Affarsvarlde